EZH2、EAF2在NSCLC中的表达及意义
|
摘要
目的探讨果蝇Zeste基因增强人类同源物(Enhancer of Zeste Homolog,EZH2)、RNA聚合酶2延长因子相关因子-2(RNA polymeraseⅡelongation factor-associated factor 2,EAF2)在非小细胞肺癌(NSCLC)中的表达及意义。方法选取2016年1月至2018年3月我院保存的NSCLC组织110例,同时选取癌旁组织作为对照,采用免疫组化染色法检测EZH2、EAF2表达。结果 NSCLC组织EZH2阳性表达率为61.82%,明显高于癌旁组织(P<0.05),而EAF2阳性表达率为34.55%,明显低于癌旁组织(P<0.05);Ⅲ期、中低分化、有淋巴结转移患者EZH2阳性表达率分别为83.33%、76.32%和86.54%,明显高于Ⅰ-Ⅱ期、高分化、无淋巴结转移患者(P<0.05),而EAF2阳性表达率分别为11.11%、15.79%和15.38%,明显低于Ⅰ-Ⅱ期、高分化、无淋巴结转移患者(P<0.05);EZH2和EAF2表达呈负相关(r_s=-0.531,P<0.05)。结论 EZH2在NSCLC中呈高表达,而EAF2呈低表达,与患者临床病理特征有一定的相关性。
Objective To investigate the expression and significance of Enhancer of Zeste Homolog( EZH2), RNA polymerase Ⅱ elongation factor-associated factor 2(EAF2) in non small cell lung cancer(NSCLC). Methods 110 NSCLC tissues preserved in our hospital from January 2016 to March 2018 were selected and the para cancerous tissue was selected as the control group. The expression of EZH2 and EAF2 were detected by immunohistochemical staining. Results The positive expression rate of EZH2 in NSCLC tissue was 61.82%, which was significantly higher than that of para cancerous tissue(P<0.05), while the positive rate of EAF2 was 34.55%, which was significantly lower than that of para cancerous tissue(P<0.05). The positive expression rates of EZH2 in patients with stage Ⅲ, middle and low differentiation and lymph node metastasis were 83.33%, 76.32% and 86.54%, which were significantly higher than those of stage I to Ⅱ, high differentiation and no lymph node metastasis(P<0.05), while the positive expression rates of EAF2 were 11.11%, 15.79% and 15.38%, which were significantly lower than those of stage I to Ⅱ, high differentiation and no lymph node metastasis(P<0.05). There was a negative correlation between EZH2 and EAF2 expression(r_s=-0.531, P<0.05). Conclusion EZH2 is highly expressed in NSCLC, while EAF2 is low expressed, which has a certain correlation with clinicopathological features.
Objective To investigate the expression and significance of Enhancer of Zeste Homolog( EZH2), RNA polymerase Ⅱ elongation factor-associated factor 2(EAF2) in non small cell lung cancer(NSCLC). Methods 110 NSCLC tissues preserved in our hospital from January 2016 to March 2018 were selected and the para cancerous tissue was selected as the control group. The expression of EZH2 and EAF2 were detected by immunohistochemical staining. Results The positive expression rate of EZH2 in NSCLC tissue was 61.82%, which was significantly higher than that of para cancerous tissue(P<0.05), while the positive rate of EAF2 was 34.55%, which was significantly lower than that of para cancerous tissue(P<0.05). The positive expression rates of EZH2 in patients with stage Ⅲ, middle and low differentiation and lymph node metastasis were 83.33%, 76.32% and 86.54%, which were significantly higher than those of stage I to Ⅱ, high differentiation and no lymph node metastasis(P<0.05), while the positive expression rates of EAF2 were 11.11%, 15.79% and 15.38%, which were significantly lower than those of stage I to Ⅱ, high differentiation and no lymph node metastasis(P<0.05). There was a negative correlation between EZH2 and EAF2 expression(r_s=-0.531, P<0.05). Conclusion EZH2 is highly expressed in NSCLC, while EAF2 is low expressed, which has a certain correlation with clinicopathological features.
引文
[1] 裴筱涵,沈勤,周晓军.周围型肺鳞状细胞癌的临床病理研究进展[J].中华病理学杂志,2017,46(12):877-880.
[2] TAKEDA M,SAKAI K,HAYASHI H,et al.Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2[J].Oncotarget,2018,9(30):21132-21140.
[3] 刘贤忠,张丽婷,童卫泉,等.肺癌侵袭和转移分子机制研究进展[J].中国医学科学院学报,2016,38(1):108-112.
[4] 曹春雨,杨凡,王艳林.EZH2与肿瘤的研究进展[J].生命的化学,2016,36(5):596-600.
[5] 安世民,丁旭苹,朱亮.非小细胞肺癌分子分型与信号调控网络[J].中国新药杂志,2015,24(24):2797-2802.
[6] 陈静,李春艳,赵苗青,等.EZH2蛋白在卵巢上皮性肿瘤中的表达及其作用[J].山东大学学报(医学版),2015,53(2):65-70.
[7] CAMIDGE D R,KIM D W,TISEO M,et al.Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials[J].J Clin Oncol,2018,36(26):2693-2701.
[8] LIN S Y,YANG C Y,LIAO B C,et al.Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab:real-world data in Taiwan[J].J Cancer,2018,9(10):1813-1820.
[9] 隋东江,王蓉美,李海燕.EGFR-TKI治疗对NSCLC患者血清CEA的影响[J].癌症进展,2017,15(8):923-925,928.
[10] SHIRAHASHI K,YAMAMOTO H,MATSUMOTO M,et al.Thoracoscopic segmentectomy:hybrid approach for clinical stage Ⅰ non-small cell lung cancer[J].J Thorac Dis,2018,10(S10):1235-1241.
[11] 杨文,马小猛,李倩,等.多价EZH2肿瘤相关抗原肽的制备及其抗原性[J].中国生物制品学杂志,2015,28(10):1033-1038.
[12] 陶丹,石远凯,韩晓红.肺鳞癌分子靶点研究进展[J].中华病理学杂志,2015,44(6):433-437.
[13] 郑娟,周梁.HOX转录反义RNA与EZH2分子在肿瘤中的研究进展[J].复旦学报(医学版),2015,42(6):795-800.
[14] 李馨,李学军.染色体调节因子EZH2对肿瘤的表观调控及靶向EZH2肿瘤治疗药物[J].中国药理学与毒理学杂志,2016,30(12):1273-1281.
[15] 吴少华,单丽珠,王华庆.表观遗传调控因子SNF5和EZH2在肿瘤发生发展中的研究进展[J].国际肿瘤学杂志,2014,41(7):488-492.
[2] TAKEDA M,SAKAI K,HAYASHI H,et al.Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2[J].Oncotarget,2018,9(30):21132-21140.
[3] 刘贤忠,张丽婷,童卫泉,等.肺癌侵袭和转移分子机制研究进展[J].中国医学科学院学报,2016,38(1):108-112.
[4] 曹春雨,杨凡,王艳林.EZH2与肿瘤的研究进展[J].生命的化学,2016,36(5):596-600.
[5] 安世民,丁旭苹,朱亮.非小细胞肺癌分子分型与信号调控网络[J].中国新药杂志,2015,24(24):2797-2802.
[6] 陈静,李春艳,赵苗青,等.EZH2蛋白在卵巢上皮性肿瘤中的表达及其作用[J].山东大学学报(医学版),2015,53(2):65-70.
[7] CAMIDGE D R,KIM D W,TISEO M,et al.Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials[J].J Clin Oncol,2018,36(26):2693-2701.
[8] LIN S Y,YANG C Y,LIAO B C,et al.Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab:real-world data in Taiwan[J].J Cancer,2018,9(10):1813-1820.
[9] 隋东江,王蓉美,李海燕.EGFR-TKI治疗对NSCLC患者血清CEA的影响[J].癌症进展,2017,15(8):923-925,928.
[10] SHIRAHASHI K,YAMAMOTO H,MATSUMOTO M,et al.Thoracoscopic segmentectomy:hybrid approach for clinical stage Ⅰ non-small cell lung cancer[J].J Thorac Dis,2018,10(S10):1235-1241.
[11] 杨文,马小猛,李倩,等.多价EZH2肿瘤相关抗原肽的制备及其抗原性[J].中国生物制品学杂志,2015,28(10):1033-1038.
[12] 陶丹,石远凯,韩晓红.肺鳞癌分子靶点研究进展[J].中华病理学杂志,2015,44(6):433-437.
[13] 郑娟,周梁.HOX转录反义RNA与EZH2分子在肿瘤中的研究进展[J].复旦学报(医学版),2015,42(6):795-800.
[14] 李馨,李学军.染色体调节因子EZH2对肿瘤的表观调控及靶向EZH2肿瘤治疗药物[J].中国药理学与毒理学杂志,2016,30(12):1273-1281.
[15] 吴少华,单丽珠,王华庆.表观遗传调控因子SNF5和EZH2在肿瘤发生发展中的研究进展[J].国际肿瘤学杂志,2014,41(7):488-492.